Adenosquamous Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADN009 MIFTS: 55	Adenosquamous Carcinoma Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma ¹² ¹⁵ ⁷³

Mixed Adenocarcinoma and Squamous Carcinoma ¹²

Adenosquamous Cell Carcinoma ¹²

Carcinoma, Adenosquamous ⁴⁴

Carcinoma Adenosquamous ⁵⁵

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4830

MeSH ⁴⁴ D018196

NCIt ⁵⁰ C3727

SNOMED-CT ⁶⁸ 59367005

UMLS ⁷³ C0206623

Sources

Summaries for Adenosquamous Carcinoma

Disease Ontology : ¹² A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to pancreatic adenosquamous carcinoma and adenosquamous lung carcinoma. An important gene associated with Adenosquamous Carcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Developmental Biology and Cytokine Signaling in Immune system. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, pancreas and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷⁶ Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Sources

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)

#	Related Disease	Score	Top Affiliating Genes
1	pancreatic adenosquamous carcinoma	33.7	KRAS PTHLH
2	adenosquamous lung carcinoma	31.9	EGFR KRAS PIK3CA
3	adenocarcinoma	30.5	EGFR KIT KRAS MUC1 MUC4 PIK3CA
4	adenoid squamous cell carcinoma	30.4	KRT7 KRT8
5	syringocystadenoma papilliferum	30.3	KRAS MUC1
6	cervical cancer	30.3	KRT5 PIK3CA TP53 TP63
7	cystic teratoma	30.2	KRT7 NKX2-1 TP53
8	in situ carcinoma	30.2	EGFR KRT5 TP53
9	mucoepidermoid carcinoma	30.1	EGFR KRT7 MUC1 MUC4 TP63
10	intestinal perforation	30.1	KRT7 NKX2-1
11	lynch syndrome	30.1	EGFR KRAS TP53
12	teratoma	30.1	KIT KRT7 NKX2-1 TP53
13	villous adenoma	30.0	KRAS KRT8 MUC1
14	squamous cell carcinoma	29.9	EGFR MUC1 PIK3CA PTHLH TP53 TP63
15	cystadenoma	29.9	KRT7 MUC1 MUC4
16	lymphoepithelioma-like carcinoma	29.9	KRT5 KRT7 KRT8 MUC1
17	hidradenoma	29.8	KRT7 MUC1 PIK3CA
18	gastrointestinal stromal tumor	29.8	EGFR KIT KRAS TP53
19	dermoid cyst	29.8	KIT KRT7 MUC1 TP63
20	large cell neuroendocrine carcinoma	29.8	EGFR KIT KRT7 NKX2-1
21	cystadenocarcinoma	29.7	KRT7 MUC1 PIK3CA TP53
22	mucinous adenocarcinoma	29.7	EGFR KRAS KRT7 MUC1 NKX2-1
23	carcinosarcoma	29.6	KIT KRAS KRT7 MUC1 PIK3CA TP53
24	necrotizing sialometaplasia	29.6	KIT KRT5 KRT7 TP53 TP63
25	small cell carcinoma	29.6	EGFR KIT KRT7 NKX2-1 TP53
26	papilloma	29.6	KRT5 KRT7 KRT8 TP53 TP63
27	gallbladder cancer	29.6	EGFR KRAS MUC1 PIK3CA TP53
28	small cell cancer of the lung	29.5	EGFR KIT KRT7 NKX2-1 PIK3CA TP53
29	endometrial cancer	29.1	AR EGFR KIT KRAS KRT7 PIK3CA
30	lung cancer	28.6	EGFR KIT KRAS KRT7 MUC4 NKX2-1
31	breast cancer	28.2	AR EGFR KIT KRAS KRT5 KRT8
32	glassy cell variant cervical adenosquamous carcinoma	12.4
33	endometrial adenosquamous carcinoma	12.4
34	gastric adenosquamous carcinoma	12.3
35	cervical adenosquamous carcinoma	12.3
36	esophageal adenosquamous carcinoma	12.3
37	thymus adenosquamous carcinoma	12.3
38	bartholin's gland adenosquamous carcinoma	12.2
39	ampulla of vater adenosquamous carcinoma	12.1
40	adenosquamous colon carcinoma	11.7
41	adenosquamous prostate carcinoma	11.6
42	adenosquamous gallbladder carcinoma	11.3
43	adenosquamous breast carcinoma	11.1
44	adenosquamous bile duct carcinoma	11.1
45	paronychia	10.3	EGFR KRAS
46	duodenum adenocarcinoma	10.3	KRAS KRT7
47	hepatoid adenocarcinoma	10.3	EGFR MUC1
48	appendix disease	10.3	KRAS KRT7
49	breast scirrhous carcinoma	10.3	EGFR MUC1
50	malignant peritoneal mesothelioma	10.3	EGFR MUC1

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:

Sources

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	9.58	EGFR KRAS MUC1 PIK3CA
2	Decreased viability	GR00106-A-0	9.58	KRAS
3	Decreased viability	GR00221-A-1	9.58	EGFR KRAS PIK3CA
4	Decreased viability	GR00221-A-2	9.58	KRAS PIK3CA
5	Decreased viability	GR00221-A-4	9.58	EGFR PIK3CA
6	Decreased viability	GR00301-A	9.58	KRAS
7	Decreased viability	GR00381-A-1	9.58	KRAS
8	Decreased viability	GR00402-S-2	9.58	EGFR KRAS MUC1 PIK3CA

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

⁴⁶ (show all 25)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.32	AR EGFR KIT KRAS KRT8 NKX2-1
2	growth/size/body region	MP:0005378	10.32	AR EGFR KIT KRAS KRT5 KRT8
3	cellular	MP:0005384	10.31	AR EGFR KIT KRAS KRT7 NKX2-1
4	digestive/alimentary	MP:0005381	10.3	AR EGFR KIT KRAS KRT5 KRT8
5	homeostasis/metabolism	MP:0005376	10.3	AR EGFR KIT KRAS KRT7 KRT8
6	behavior/neurological	MP:0005386	10.28	AR KIT KRAS KRT5 NKX2-1 PIK3CA
7	endocrine/exocrine gland	MP:0005379	10.24	AR EGFR KIT KRAS NKX2-1 PIK3CA
8	mortality/aging	MP:0010768	10.24	AR EGFR KIT KRAS KRT5 KRT8
9	craniofacial	MP:0005382	10.21	AR EGFR KIT KRAS KRT5 PTHLH
10	immune system	MP:0005387	10.2	AR EGFR KIT KRAS KRT8 PIK3CA
11	embryo	MP:0005380	10.19	AR EGFR KIT KRAS KRT8 PIK3CA
12	integument	MP:0010771	10.19	AR EGFR KIT KRAS KRT5 PIK3CA
13	limbs/digits/tail	MP:0005371	10.13	AR EGFR KIT KRAS KRT5 PTHLH
14	neoplasm	MP:0002006	10.11	AR EGFR KIT KRAS NKX2-1 PIK3CA
15	liver/biliary system	MP:0005370	10.05	AR EGFR KIT KRAS KRT8 PTHLH
16	no phenotypic analysis	MP:0003012	10.03	EGFR KIT KRAS KRT5 NKX2-1 PIK3CA
17	muscle	MP:0005369	10.02	AR EGFR KIT KRAS PIK3CA TP53
18	normal	MP:0002873	10.01	AR EGFR KIT KRAS NKX2-1 PTHLH
19	hearing/vestibular/ear	MP:0005377	9.97	EGFR KIT KRAS KRT8 TP53
20	reproductive system	MP:0005389	9.96	AR EGFR KIT KRAS KRT8 NKX2-1
21	renal/urinary system	MP:0005367	9.92	AR EGFR KIT KRAS KRT7 PTHLH
22	pigmentation	MP:0001186	9.77	AR EGFR KIT KRAS TP53
23	respiratory system	MP:0005388	9.7	EGFR KIT KRAS NKX2-1 PTHLH TP53
24	skeleton	MP:0005390	9.61	AR EGFR KIT KRAS NKX2-1 PIK3CA
25	vision/eye	MP:0005391	9.17	EGFR KIT KRAS PIK3CA PTHLH TP53

Sources

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Epoetin alfa

Phase 4,Phase 3

113427-24-0

Hematinics

Phase 4,Phase 3

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Topotecan

Approved, Investigational

Phase 3,Phase 2,Phase 1

123948-87-8, 119413-54-6

60700

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

216974-75-3

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

60780 44424639

Gemcitabine

Approved

Phase 3,Phase 2,Phase 1

95058-81-4

60750

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Lenograstim

Approved, Investigational

Phase 3,Phase 2,Phase 1

135968-09-1

Doxorubicin

Approved, Investigational

Phase 3,Phase 1

23214-92-8

31703

Vindesine

Approved, Investigational

Phase 3

59917-39-4, 53643-48-4

40839

leucovorin

Approved

Phase 3,Phase 2

58-05-9

6006 143

Fluorouracil

Approved

Phase 3,Phase 1,Phase 2

51-21-8

3385

Bleomycin

Approved, Investigational

Phase 3

11056-06-7

5360373

Methotrexate

Approved

Phase 3

59-05-2, 1959-05-2

126941

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Mecasermin

Approved, Investigational

Phase 3

68562-41-4

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2

59-30-3

6037

Doxil

Approved June 1999

Phase 3,Phase 1

31703

Tirapazamine

Investigational

Phase 3,Phase 2,Phase 1

27314-97-2

Immunologic Factors

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

insulin

Phase 3

Insulin, Globin Zinc

Phase 3

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1

Immunoglobulin G

Phase 3,Phase 2,Phase 1

topoisomerase I inhibitors

Phase 3,Phase 2,Phase 1

Endothelial Growth Factors

Phase 3,Phase 2,Phase 1

Mitogens

Phase 3,Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Anti-Infective Agents

Phase 3,Phase 2,Phase 1

Antiviral Agents

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Adjuvants, Immunologic

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Isophosphamide mustard

Phase 3

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2

Folic Acid Antagonists

Phase 3,Phase 2

Alkylating Agents

Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 106)

#	Name	Status	NCT ID	Phase	Drugs
1	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer	Completed	NCT00046969	Phase 4	cisplatin
2	Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	Completed	NCT00803062	Phase 3	Cisplatin;Paclitaxel;Topotecan Hydrochloride
3	Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix	Completed	NCT00064077	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5	Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia	Completed	NCT00017004	Phase 3	Cisplatin
6	Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer	Completed	NCT00003209	Phase 3	cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7	Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	Completed	NCT00003945	Phase 3	cisplatin;topotecan hydrochloride
8	Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery	Completed	NCT00002807	Phase 3
9	Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix	Completed	NCT00003078	Phase 3	cisplatin;fluorouracil
10	Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer	Completed	NCT00002493	Phase 3	cisplatin;doxorubicin hydrochloride
11	Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer	Completed	NCT00006027	Phase 3	cisplatin;paclitaxel
12	Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery	Recruiting	NCT01101451	Phase 3	Cisplatin
13	Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy	Recruiting	NCT00980954	Phase 3	carboplatin;cisplatin;paclitaxel
14	Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix	Active, not recruiting	NCT01365156	Phase 3
15	Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer	Active, not recruiting	NCT01414608	Phase 3	Carboplatin;Cisplatin;Paclitaxel
16	Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer	Active, not recruiting	NCT00039338	Phase 3	cisplatin
17	Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology	Terminated	NCT00596830	Phase 3	CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
18	Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer	Terminated	NCT01363466	Phase 3
19	Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix	Terminated	NCT00054067	Phase 3	cisplatin
20	Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer	Terminated	NCT00262821	Phase 3	cisplatin;tirapazamine
21	Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer	Terminated	NCT00085631	Phase 3	cisplatin
22	Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer	Unknown status	NCT00008112	Phase 2	cisplatin
23	Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer	Unknown status	NCT01158248	Phase 2	cisplatin
24	Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer	Unknown status	NCT00462397	Phase 2	carboplatin;cisplatin;paclitaxel
25	Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix	Completed	NCT00005965	Phase 2	bryostatin 1;cisplatin
26	Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT00039442	Phase 2	Capecitabine
27	Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01011933	Phase 2	Selumetinib
28	Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
29	Ixabepilone to Treat Cervical Cancer	Completed	NCT00924066	Phase 2	Ixempra (Ixabepilone (BMS-247550) )
30	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
31	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01132820	Phase 2	Cediranib Maleate
32	ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT00309959	Phase 2	Paclitaxel Albumin-Stabilized Nanoparticle Formulation
33	Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2
34	Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery	Completed	NCT00389974	Phase 2	sunitinib malate
35	Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer	Completed	NCT00057863	Phase 2	Paclitaxel;Oxaliplatin
36	S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer	Completed	NCT00003369	Phase 2	cisplatin;tirapazamine
37	Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer	Completed	NCT00004251	Phase 2	letrozole
38	Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer	Completed	NCT00030485	Phase 2	erlotinib hydrochloride
39	Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT01266447	Phase 2	Topotecan Hydrochloride;Veliparib
40	Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery	Completed	NCT01026792	Phase 2	Temsirolimus
41	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer	Completed	NCT01210222	Phase 2
42	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
43	Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer	Completed	NCT00369122	Phase 2	Cisplatin
44	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Completed	NCT00064025	Phase 2	Medroxyprogesterone
45	Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00025467	Phase 2	thalidomide
46	S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer	Completed	NCT00003127	Phase 2	amifostine trihydrate;carboplatin;paclitaxel
47	Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer	Completed	NCT00005070	Phase 2	irofulven
48	Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix	Completed	NCT00003017	Phase 2
49	Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer	Completed	NCT00002916	Phase 2
50	Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Sources

Genetic Tests for Adenosquamous Carcinoma

Sources

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

⁴¹

Cervix, Pancreas, Lung, Breast, Colon, Liver, Prostate

Sources

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 553)

#	Title	Authors	Year
1	Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database. ( 29878370 )	Hester C.A....Yopp A.C.	2018
2	A retroperitoneal mass confirmed as a pancreatic adenosquamous carcinoma by endoscopic ultrasound-guided fine-needle aspiration. ( 29069702 )	Lopes C.V....Hartmann A.A.	2018
3	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. ( 29609906 )	Liu Y....Hirsch F.R.	2018
4	A Rare Case of Penile Metastases as a Harbinger of Primary Pulmonary Adenosquamous Carcinoma. ( 29785317 )	Hota P....Agosto O.	2018
5	High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. ( 29537649 )	Bataillon G....Vincent-Salomon A.	2018
6	Clinicopathological characteristics and survival outcomes in adenosquamous carcinoma of the lung: a population-based study from the SEER database. ( 29487721 )	Wang J....Song Y.	2018
7	Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes. ( 29850145 )	Zhu L....He J.	2018
8	Adenosquamous Carcinoma in the Midline Dorsum of the Tongue: A Rare Case Report. ( 29806990 )	Kikuta S....Kusukawa J.	2018
9	Pancreatic adenosquamous carcinoma masquerading as a locally invading splenic abscess. ( 29740918 )	Kim T.J....Gilmore A.	2018
10	Long-term survival with extended lateral lymphadenectomy for lateral lymph node recurrence after laparoscopic abdominoperineal resection for rectal adenosquamous carcinoma: a case report. ( 29633041 )		2018
11	Adenosquamous carcinoma of the bile duct: a population-based study. ( 29563834 )		2018
12	Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. ( 30516569 )	Jin Z...Yoon HH	2018
13	Colonic adenosquamous carcinoma and mucinous adenocarcinoma with microsatellite instability. ( 30173239 )	Parra-Medina R...Polo F	2018
14	Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report. ( 29983579 )	Li A...Yu C	2018
15	Adenosquamous Carcinoma of the Esophagus: A Literature Review. ( 29984200 )	Schizas D...Mylonas KS	2018
16	Adenosquamous Carcinoma of the Ampulla of Vater: A Rare Cause of Obstructive Jaundice. ( 29998166 )	Carvalho L...Chagas C	2018
17	Uncommon Types of Lung Carcinoma With Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. ( 30040455 )	Borczuk AC	2018
18	Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. ( 30100056 )	Hlaing AM...Fukuoka J	2018
19	Adenosquamous carcinoma of the right colon: A case report and review of the literature. ( 30103094 )	Toumi O...Zouari K	2018
20	Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma. ( 30122989 )	Zhang C...Zhang X	2018
21	"Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of CRTC1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary Gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features. ( 30138216 )	Saeki K...Oda Y	2018
22	Adenosquamous carcinoma of the lung. ( 30147334 )	Li C...Lu H	2018
23	Adenosquamous carcinoma arising in a duplication cyst of the gallbladder. ( 30221164 )	Ariche A...Dreznik Y	2018
24	Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases. ( 30258209 )	Stolnicu S...Soslow RA	2018
25	Survival analysis for lung adenosquamous carcinoma patients with brain metastasis. ( 30405840 )	Pan F...Jiang L	2018
26	Research progress of the clinicopathologic features of lung adenosquamous carcinoma. ( 30410358 )	Wang J...Li D	2018
27	Adenosquamous carcinoma of the papilla of Vater: A phenotypic heterogeneity characterized by a common molecular landscape. ( 30417956 )	Milanetto AC...Pasquali C	2018
28	Low-grade Adenosquamous Carcinoma of the Breast: A Case Report. ( 30449342 )	Delgado Hardegree LA...Gulla S	2018
29	Adenosquamous Carcinoma of the Anus: An Uncommon Malignancy Presenting a Treatment Challenge. ( 30454337 )	Johnson M...Orucevic A	2018
30	PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component. ( 30477643 )	Tanigawa M...Yano H	2018
31	Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. ( 28848104 )	Evans M....Saba N.F.	2017
32	Gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor: a case of a rare malignancy. ( 28493097 )	Moro K....Wakai T.	2017
33	Adenosquamous Carcinoma of the Pancreas Demonstrated on 18F-FDG PET/CT Imaging. ( 28098663 )	Jiang L....Shi H.	2017
34	Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection. ( 28123305 )	Fan L....Zhao H.	2017
35	Primary Hepatic Adenosquamous Carcinoma Associated with Primary Sclerosing Cholangitis. ( 29258074 )	Yamao K....Kudo M.	2017
36	Expression of hormone receptors in low-grade adenosquamous carcinoma of the breast: A case report. ( 29145336 )	Wu H.B....Li H.	2017
37	CD117 expression in adenosquamous carcinoma. ( 28766737 )	Panse G....Ko C.J.	2017
38	Genomic signatures of pancreatic adenosquamous carcinoma (PASC). ( 28722109 )	Fang Y....Shen B.	2017
39	Clinical implications of the proliferative ability of the squamous component regarding tumor progression of adenosquamous carcinoma of the pancreas: A preliminary report. ( 28784574 )	Hoshimoto S....Ogata Y.	2017
40	Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a<i>CDKN2A</i>germline mutation carrier. ( 28979722 )	MartA-nez de Juan F....Machado I.	2017
41	Importance of tumor extent in adenosquamous carcinoma of the head and neck: a retrospective cohort study. ( 28412233 )	Lee R.J....Christensen R.E.	2017
42	Atypical breast adenosquamous carcinoma following acute myeloid leukemia in a middle-aged woman: A case report. ( 28357109 )	Hashemi S.M....Allahyari A.	2017
43	Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. ( 28816351 )	Marcus R....Roszik J.	2017
44	Clinicopathological features and prognosis of gastric adenosquamous carcinoma. ( 28676632 )	Feng F....Zhang H.	2017
45	Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 28465645 )	Wu Z.C....Yang Z.L.	2017
46	Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report. ( 28489796 )	Lu Y.F....Hsieh C.H.	2017
47	The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma. ( 28397462 )	Jin X....Lu H.	2017
48	Spontaneous pulmonary adenosquamous carcinoma in a free-living black capuchin monkey (Sapajus nigritus). ( 29283438 )	DA-az-Delgado J....CatALo-Dias J.L.	2017
49	Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. ( 29203990 )	Gulwani H.V....Kaur S.	2017
50	Adenosquamous Carcinoma of the Colon. ( 29606937 )		2017

Sources

Genes for Adenosquamous Carcinoma

Genes related to Adenosquamous Carcinoma (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	KRT7	Keratin 7	Protein Coding	30.2	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19278431 19444077 19859629
2	EGFR	Epidermal Growth Factor Receptor	Protein Coding	30.15	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17186532 19563658 7528164 (more) 8459036 7654016 17581404 18992960 17069674 19514842 17238183 9588219 16187277
3	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	28.32	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17090193
4	KRT8	Keratin 8	Protein Coding	27.37	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	1715731 1724841
5	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	26.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7671236 9020567 8107631 (more) 18836809 2348564 11506305 15864702
6	MUC4	Mucin 4, Cell Surface Associated	Protein Coding	25.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17425390 17090193
7	TP63	Tumor Protein P63	Protein Coding	25.01	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19278431 12210069 11381365 (more) 16484002 19444077
8	KRT5	Keratin 5	Protein Coding	23.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	22.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	AR	Androgen Receptor	Protein Coding	22.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12558872
11	TP53	Tumor Protein P53	Protein Coding	22.36	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	21.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	Protein Coding	21.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	NKX2-1	NK2 Homeobox 1	Protein Coding	21.06	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17036524 11224607 15084379 (more) 19444077

Sources

Variations for Adenosquamous Carcinoma

Sources

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Sources

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 40)

#	Super pathways	Score	Top Affiliating Genes
1	Developmental Biology ⁶⁶ Show member pathways Axon guidance ⁶⁶	13.3	EGFR KIT KRAS KRT5 KRT7 KRT8
2	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.25	EGFR KIT KRAS MUC1 PIK3CA TP53
3	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.86	EGFR KIT KRAS PIK3CA TP53
4	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.81	EGFR KIT KRAS PIK3CA TP53
5	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.56	EGFR KIT KRAS PIK3CA TP53
6	Downstream signaling events of B Cell Receptor (BCR) ⁶⁶ Show member pathways Activation of RAS in B cells ⁶⁶ Signaling by the B Cell Receptor (BCR) ⁶⁶	12.51	EGFR KIT KRAS PIK3CA TP53
7	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.47	EGFR KRAS PIK3CA TP53
8	Cytoskeletal Signaling ⁴	12.4	KRT5 KRT7 KRT8 MUC1
9	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.38	AR EGFR KIT KRAS PIK3CA TP53
10	mTOR signaling pathway (KEGG) ⁶⁵ Show member pathways mTOR signaling pathway ³⁷	12.35	EGFR KRAS PIK3CA TP53
11	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.33	EGFR KRAS PIK3CA TP53
12	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.28	EGFR KRAS PIK3CA TP53
13	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.25	EGFR KRAS MUC1 PIK3CA TP53
14	Phospholipase D signaling pathway ³⁷ Show member pathways Choline metabolism in cancer ³⁷	12.21	EGFR KIT KRAS PIK3CA
15	Immune response IFN alpha/beta signaling pathway ²² Show member pathways Cytokine Network ⁶⁴ Interferon alpha/beta signaling ⁶⁶ Regulation of IFNA signaling ⁶⁶	12.15	EGFR KIT KRAS TP53
16	Pathways in cancer ³⁷	12.15	AR EGFR KIT KRAS PIK3CA TP53
17	MicroRNAs in cancer ³⁷	12.13	EGFR KRAS PIK3CA TP53 TP63
18	Proteoglycans in cancer ³⁷	12.11	EGFR KRAS PIK3CA TP53
19	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.05	EGFR KRAS PIK3CA TP53
20	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12	EGFR KRAS PIK3CA
21	Direct p53 effectors ¹	11.97	EGFR TP53 TP63
22	MAPK Pathway ⁷² Show member pathways Toll-like Receptor Pathway ⁷²	11.94	EGFR PIK3CA TP53
23	Integrated Breast Cancer Pathway ¹	11.92	AR EGFR KRAS TP53
24	Sphingolipid signaling pathway ³⁷	11.91	KRAS PIK3CA TP53
25	AKT Signaling Pathway ⁶⁷	11.91	EGFR KRAS PIK3CA TP53
26	Thyroid hormone signaling pathway ³⁷	11.9	KRAS PIK3CA TP53
27	DNA Damage Response (only ATM dependent) ¹	11.88	KRAS PIK3CA TP53
28	Glioblastoma Multiforme ⁶⁴	11.86	EGFR KRAS TP53
29	Cytoskeleton remodeling Neurofilaments ²² Show member pathways Cytoskeleton remodeling Keratin filaments ²²	11.84	KRT5 KRT7 KRT8
30	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.83	EGFR KRAS PIK3CA
31	Hepatitis C ³⁷	11.82	EGFR KRAS PIK3CA TP53
32	Jak-Stat Signaling Pathway (sino) ⁶⁷	11.79	EGFR KRAS PIK3CA
33	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants ⁶⁶ Show member pathways Constitutive Signaling by EGFRvIII ⁶⁶ Signaling by EGFR in Cancer ⁶⁶ Signaling by EGFRvIII in Cancer ⁶⁶ Signaling by Ligand-Responsive EGFR Variants in Cancer ⁶⁶	11.74	EGFR KRAS PIK3CA
34	VEGF Pathway (Tocris) ⁶¹ Show member pathways VEGF Pathway ⁷²	11.67	KIT KRAS PIK3CA
35	Bladder cancer ³⁷ ¹	11.58	EGFR KRAS TP53
36	Transcription_Transcription factor Tubby signaling pathways ²²	11.19	EGFR KRAS TP53
37	E-cadherin signaling in keratinocytes ¹	10.96	EGFR PIK3CA
38	Nongenotropic Androgen signaling ¹	10.93	AR PIK3CA
39	G-protein signaling_K-RAS regulation pathway ²²	10.93	EGFR KRAS PIK3CA
40	Central carbon metabolism in cancer ³⁷	10.83	EGFR KIT KRAS PIK3CA TP53

Sources

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	9.4	AR EGFR KIT KRAS KRT5 KRT7
2	keratin filament	GO:0045095	9.33	KRT5 KRT7 KRT8
3	nuclear chromatin	GO:0000790	9.26	AR MUC1 TP53 TP63

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	cell proliferation	GO:0008283	9.88	AR EGFR TP53 TP63
2	positive regulation of transcription, DNA-templated	GO:0045893	9.88	AR EGFR NKX2-1 TP53 TP63
3	positive regulation of cell proliferation	GO:0008284	9.8	AR EGFR KIT KRAS PTHLH
4	positive regulation of MAPK cascade	GO:0043410	9.77	AR EGFR KIT
5	phosphatidylinositol phosphorylation	GO:0046854	9.73	EGFR KIT PIK3CA
6	cornification	GO:0070268	9.72	KRT5 KRT7 KRT8
7	positive regulation of gene expression	GO:0010628	9.65	AR KIT KRAS NKX2-1 TP53
8	liver development	GO:0001889	9.63	EGFR KRAS PIK3CA
9	epithelial tube branching involved in lung morphogenesis	GO:0060441	9.58	KRAS NKX2-1
10	prostate gland development	GO:0030850	9.57	AR TP63
11	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.54	MUC1 TP53
12	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.54	KRAS MUC1 MUC4
13	tongue development	GO:0043586	9.52	EGFR KIT
14	cerebral cortex cell migration	GO:0021795	9.51	EGFR NKX2-1
15	positive regulation of MAP kinase activity	GO:0043406	9.5	EGFR KIT KRAS
16	Leydig cell differentiation	GO:0033327	9.49	AR NKX2-1
17	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.43	EGFR TP53
18	cytokine-mediated signaling pathway	GO:0019221	9.35	KIT KRAS MUC1 PIK3CA TP53
19	morphogenesis of an epithelial fold	GO:0060571	9.16	AR EGFR
20	epidermis development	GO:0008544	8.92	EGFR KRT5 PTHLH TP63

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	9.56	AR EGFR NKX2-1 TP53
2	transcription regulatory region DNA binding	GO:0044212	9.46	AR NKX2-1 TP53 TP63
3	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.13	EGFR KIT PIK3CA
4	p53 binding	GO:0002039	8.8	MUC1 TP53 TP63

Sources

Sources for Adenosquamous Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia